
Turkish
Biopharmaceuticals
Platform
www.biopharma.org.tr

Turkish Biopharmaceuticals Platform

June 2018

Turkish Biopharmaceuticals Platform

Turkish Biopharmaceuticals Platform

Turkish Biopharmaceuticals Platform

The Platform was established by Turkish Pharmaceutical Manufacturers Association (IEIS) in 2016 with the participation of companies in the biotechnology field. Its main purpose is to contribute to the development of biopharmaceuticals field in Turkey.

The main activities of the Turkish Biopharmaceuticals Platform are as follows:

- Contributing to the creation of a supportive regulatory environment,
- Trying to establish an effective incentive scheme,
- Improving the cooperation between public, private and academic institutions,
- Initiating pre-competition cooperation among member firms,
- Improving health professionals' knowledge and awareness,
- Collaborating with national and international NGO's,
- Organizing local and international biotechnological events.

Company Name:
Abdi İbrahim Pharmaceuticals
Company Web:
www.abdiibrahim.com.tr

Turkish Biopharmaceuticals Platform

Pharmacist Abdi İbrahim Bey started his "healing" journey and laid the foundations for Abdi İbrahim, the leader in the Turkish pharmaceutical industry, at a small pharmacy in Küçükmustafapaşa neighborhood of Istanbul in 1912. Abdi İbrahim not only works with nearly 30 licensors but also develops its own products. It has the broadest product portfolio in the sector with more than 180 brands and 350 products.

Thanks to its strong vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of the Turkish pharmaceutical industry since 2002. Abdi İbrahim is currently operating through its own organizational structure in 12 countries in addition to Turkey. It exports to 50 countries ranging from the European Union countries to Canada, from Africa to Asia and creates the highest employment in the Turkish pharmaceutical industry with its 4.000 qualified employees.

AbdiBio, the largest pharmaceutical production facility in Turkey that launched operations on May 11, 2018 following an investment of TRY 400 million, will produce biotechnological pharmaceuticals which will both be used in Turkey and be exported, thus making a contribution to the current account deficit. Established on a total indoor area of 13,000 square meters, AbdiBio will offer a base where all stages of production from cell banks to the end product will be performed. AbdiBio has an annual production capacity of 11 million vials, 9 million syringes, 22 million cartridges and 1 million lyophilized materials. AbdiBio will produce biotechnological pharmaceuticals for diseases such as cancer, diabetes, central nervous system diseases and blood diseases that cannot be treated with chemical drugs and emerges as a promising step for the future of the Turkish pharmaceutical industry.

Embodying the best technologies observed around the world and at its business partners, generating local know-how and ensuring product diversity so as to create long-term value through value-added and innovative products are the fundamental elements of AbdiBio's strategy.

Maintaining lead in the Turkish pharmaceutical industry, Abdi İbrahim increases its efficiency on international markets each day and uninterruptedly sustains operations in order to become one of the top 100 pharma companies in the world in addition to retaining its strong leading position at the national level.

Contact Person
Name: Buket Koral
Position: Corporate Communications Manager
Phone: +90 532 743 82 73
E-mail: buket.koral@abdiibrahim.com.tr

Adeka was founded in Samsun on December 6, 1956 as the first Turkish pharmaceutical company that manufactures in Anatolia. The production is being carried out in the facility which was modernized in Samsun in 1995, in the covered area of 4000 m^2 and the construction of the new facility is still on going in Samsun.

Adeka represents world's leading pharmaceutical companies in Turkey. In addition to its own pharmaceuticals, it also manufactures their pharmaceuticals in its own facilities and markets them.

With modern production techniques and technology, it has a production capacity of 65 million boxes per year in accordance with cGMP and GLP standards.

Contact Person

Name: Melih Gürsoy
Position: General Manager
Phone: +90 212 365 08 00
E-mail: melih.gursoy@adeka.com.tr

Name: Şule İmer
Position: Regulatory Affairs Director
Phone: +90 212 365 08 00
E-mail: sule.imer@adeka.com.tr

Name: Aslı Acar
Position: Medical Manager
Phone: +90 212 365 08 00
E-mail: asli.acar@adeka.com.tr

Company Name:
Adeka Pharmaceuticals
Company Web:
www.adeka.com.tr

Company Name:
Ali Raif Pharmaceuticals
Company Web:
www.aliraif.com.tr

Ali Raif Pharmaceuticals (ARIS), which was established under the name of Ali Raif ve Seriki in 1928, was reorganized to trade in Turkish pharmaceutical industry by Muzaffer Turhan as of 1963.

It has 195 different pharmaceutical forms that contribute in enhancing the quality of life thanks to their therapeutic fields such as cardiovascular, diabetics, gastrointestinal, analgesic, anti-inflammatory, anti-flu, antiviral, antihistaminic, central nervous system, transplantation products. It has been serving Turkish Pharmaceutical Industry for 55 years with its qualified pharmaceutical production and institutional stance and continues to cooperate with global companies.

Ali Raif Pharmaceuticals aims to always offer better service to its customers and partners with the mission of "Value added life". To facilitate product access to the countries it can reach both in our country and in the world, Ali Raif increases its human resources and production resources, also develops and supports them with continuous investments. Import, export production, domestic promotion and marketing activities are carried out with strong staff in Istanbul Ikitelli Production Facilities, Istanbul 4th Levent Head Office and totally 10 area offices in Turkey.

In 2010, in recognition of its social and environmental responsibilities, Ali Raif Pharmaceuticals has signed the United Nations Global Principles Agreement to support and defend its ten basic principles on human rights, labor standards, environmental management and anti-corruption.

Its R&D department, which has been conducting research and development activities for many years, continues to work as an R&D center approved by the Ministry of Science and Technology on 12 January 2017.

Ali Raif Pharmaceuticals, which is in the first 20 firms in the unit and value rank in the Turkish pharmaceutical market, has adopted the approach that always trusts ethical work and stakeholders as a standard since 55 years. Ali Raif Pharmaceuticals continues to be one of the leading players in the sector with its mission to add value to life and continues to build the future by expanding production volume within the new product portfolio and localization.

Contact Person
Name: Seda Turhan Bilen
Position: Corporate Communications Director
Phone: +90 212 316 78 00
E-mail: seda@aliraif.com.tr

Company Name:
Arven Pharmaceuticals
Company Web:
www.arvenilac.com.tr

Turkish Biopharmaceuticals Platform

Toksöz Group began making investments to launch biological medicine production in 2007. Arven Pharmaceuticals continues its efforts towards improving public health with its qualified researchers and personnel, who have experience in biosimilar product development and hold advanced degrees, and its biosimilar product development infrastructure, which continues to grow each day. Toksöz Group's manufacturing plant for high-tech products for Arven Pharmaceuticals, which is established on a closed area of 28,000 m2 in the Kırklareli Organised Industrial Zone, one of the Group's main investments in this regard, started to operate in 2017.

Arven Pharmaceuticals; a 100% Turkish capitalized pharmaceutical company, succeeded in developing the first Turkish patented dry powder inhaler "Sanohaler®" as a result of long lasting R&D activities, which is a very important milestone in Turkish Pharmaceutical Industry.

Moreover, as a result of their investments in biotechnology, Arven Pharmaceuticals succeeded in authorisating Turkey's "from cell to finished biosmilar product" that was produced and developed by Turkish pharmaceutical industry.

Greatest goal of Arven Pharmaceuticals is to produce biosimilars of expensive biological medicines in quality standards that will satisfy authorities, and to offer these products for the benefit of public health. Employing promising youth who have completed degree programs in relevant areas (Molecular Biology and Genetics, Biology, Bioengineering, etc.) to reach this goal would also prove a valuable asset for our nation.

Arven Pharmaceuticals follows guidelines published by the World Health Organization, European Medicines Agency and USA Food and Drug Administration during the biosimilar development process. The "Every Product is a Process" approach and the importance of quality during this process are the pillars of Arven Pharmaceuticals' operations. Arven Pharmaceuticals conducts the majority of structural and functional analyses recommended in international guidelines with its current infrastructure and experts in relevant fields. Reaching commercial production levels without compromising product quality is the most critical step of the development process, as well as an important mission Arven Pharmaceuticals has adopted for advancement in public health.
A new production plant for Arven will be established in Kırklareli with the motto "We design the technology for the future today, and we provide the future to human health" and in the next years, along with respiratory products, it will be able to produce specific medicine such as biotechnology, oncology and hormone medicine.

Contact Person
Name: Melda Mısırlı
Position: Group Business Development and Regulatory Affairs Director
Phone: +90 212 362 12 05
E-mail: meldamisirli@toksozgrup.com.tr

Company Name:
Atabay Pharmaceuticals and Fine Chemicals
Company Web:
www.atabay.com

Turkish Biopharmaceuticals Platform

Atabay was founded in Istanbul by Mr. Ö. Kemalettin Atabay, Pharmacist, in 1939, prior to the outbreak of the Second World War. The company had emerged as a trading business, importing and marketing pharmaceutical products. In the 1940's, this medium sized commercial operation developed into the production of sulfonamide tablets, which were in great demand at the time, thus paving the way to the pharmaceutical industry in Turkey. By 1954, Atabay Pharmaceutical Products Inc. had evolved into a well-equipped modern plant. The initial product line expanded to include analgesics, apart from sulfonamides. Atabay's rapid growth, in due time, necessitated a larger plant. Consequently, in 1967, this facility was established at its present site in Acıbadem, Istanbul.

After successful years of performance in pharmaceuticals, Mr. Bülent Atabay, Chemical Engineer and President, prompted back – integration and entered in to the manufacture of fine chemicals. In 1970, the site of Atabay Pharmaceutical Fine Chemicals Inc was chosen at Gebze, near Istanbul. Five years later, in addition to the premises for the pharmaceutical fine chemicals, extensive facilities were set up in a separate area in Gebze to produce chemicals for the agricultural, public health and veterinary fields.

In 2015, Atabay started a biotechnology Project with the support of TÜBİTAK KAMAG 1007, on the development and production of a bioengineered antibody, which continues successfully with the partnership of İTÜ MOBGAM and Marmara University. Cell line development, process development and scale-up as well as detailed analytics are carried out within the group. Atabay built a new cGMP facility dedicated to microbial manufacturing and development. Atabay will continue to develop production of enzymes, antibody fragments, and other biosimilars using microbial fermentation.

Today, the Atabay enterprises, managed by a progressive and technically trained executive staff, is fully active in producing quality products for human and animal health. Marketing and promotion of the products are accomplished by a competitive sales network with distributors in the domestic as well as international arenas.

Contact Person
Name: Zeynep Atabay Taşkent
Position: Member of Board
Phone: +90 216 326 65 33
E-mail: zatabay@atabay.com

Centurion Pharmaceuticals, which believes that every patient deserves modern treatment and high quality of life, started its journey in 1979 in cooperation with Turkey's and the world's leading institutions; offers biotechnological, biological, vaccine and specific hospital products which are placed in today's modern treatment alternatives.

Centurion Pharmaceuticals Manufacturing and R&D Facility, with an area of 26.000 m^2, is located in Ankara province and provides the development of biological, biotechnological and specific hospital products as well as production in high quality standards. The capacity of its manufacturing facility as a single shift is; 10 M vials, 5 M syringes and 3 M cartridges annually. However, in the field of biosimilars, orphan drugs and vaccine products, the company is collaborating with leading companies from all over the world and developing common projects in innovative therapeutic areas. Apart from Turkish market, export-oriented activities began in 2017, has started to give service to the markets abroad.

The product portfolio includes biosimilar products (TNF alpha blockers, EPO, interferons), specific hospital products, plasma products (Human Albumin, IVIG) and orphan drugs.
Adopting humanity, nature and respect as its core values Centurion Pharmaceuticals will continue to focus on higher goals in the coming years, with the responsibility of being a flexible, creative, competitive and business-focused company philosophy and being one of the leading companies in its field.

Contact Person
Name: Melih Altınışık
Position: Business Development Manager
Phone: +90 212 275 07 08
E-mail: melihaltinisik@centurion.com.tr

Company Name:
Centurion Pharmaceuticals
Company Web:
www.centurion.com.tr

Company Name:
CinnaGen Pharmaceuticals
Company Web:
www.cinnagenilac.com.tr

The biggest biotech company in META (Middle East, Turkey and Africa) region & the first MAB (Monoclonal Antibody) producer CinnaGen Group has recombinant peptides, proteins and MAB products those are mainly used for treatment of oncology, autoimmune diseases, rare diseases, MS, blood diseases & disorders.

Thanks to its high technology used for MAB production, CinnaGen Group has significant development in life sciences for manufacturing affordable biotechnological products at particular therapeutic areas.

In addition to its R&D and manufacturing technology CinnaGen has extensive experience and know-how of selling and marketing biosimilars to support his international distributors worldwide.

As a pioneer biotech manufacturer, CinnaGen is capable to transfer its production technology to strategic markets.

Contact Person
Name: Ferhat Farşi
Position: CEO
Phone: +90 216 504 77 27
E-mail: ferhat.farsi@cinnagenilac.com.tr

Name: Esin Altınordulu
Position: Regulatory Affairs and Market Access Director
Phone: +90 216 504 77 27
E-mail: esin.altinordulu@cinnagenilac.com.tr

Name: Onur Dal
Position: Business Development Director
Phone: +90 216 504 77 27
E-mail: onur.dal@cinnagenilac.com.tr

Company Name:
Dem Pharmaceuticals
Company Web:
www.demilac.com.tr

Based on values such as honesty, respect and trust, committed on its vision, mission and values, and being the icon of quality and trust within the pharmaceutical sector, Dem Pharmaceuticals has been established by a family devoted themselves to Turkish pharmaceutical industry since 1970. Dem Pharmaceuticals continues to give their services to the Turkish Medicine since 1992 finding effective and fast results, improving its quality and increasing the variety of its services.

Dem Pharmaceuticals, is incorporated in the Turkish pharmaceutical industry and sells imported and licensed drugs and medical preparations. The company distributes drugs to the major pharmaceutical warehouses in Turkey and across Turkey.

The product portfolio of Dem Pharmaceuticals includes blood products, anesthetic agents, plasma expanders, antibiotics, reference biotechnological and biosimilar products procured from the leading manufacturers of the world and licensed medicines for human consumption manufactured in modern plants of Turkey.

In addition to those activities, Dem Pharmaceuticals has been developing its own biosimilar, nanosimilar and peptide derivative pharmaceuticals in its own R&D Labarotories.

For manufacturing of the own-developed products and servicing as contract manufacturer; Dem Pharmaceuticals has just constructed its own high-tech biotechnological sterile manufacturing facility. The total closed area of this facility is 14756 m2 and will be planned to run in full capacity.

Dem Pharmaceuticals which is highly focused on new product research and invests in this area, holds about 100 license files for human medicines, blood products and oncology medicines. The company also holds import rights for some medical preparations with CE certificate besides the products for which it has licenses for export, manufacture and sub-manufacture.

Dem Pharmaceuticals continues to conduct researches worldwide to conclude new product agreements with licensors and to expand its portfolio in addition to products it markets and for which licensing works continue.

Dem Pharmaceuticals takes firm steps forward with the support of its dynamic, creative and qualified staff who believe in team spirit with high individual motivation and are open to innovations and developments.

Contact Person
Name: Esra Üstünyağız
Position: Scientific Department Director
Phone: +90 216 428 40 29
E-mail: esra.ustunyagiz@demilac.com.tr

Company Name:
Eczacıbaşı Pharmaceuticals Marketing
Company Web:
www.eczacibasi.com.tr

Eczacıbaşı Pharmaceuticals Marketing carries out the marketing, promotion, sales and distribution of imported and contract manufactured pharmaceuticals for mass and niche markets and health-based personal care products. Its growing portfolio currently comprises products licensed by Almirall, Arnet, Aspen, Astellas, Baxter International, Biogaia, Chugai, Edmond Pharma, Galderma, Juvise Pharmaceuticals, Pharming, Procter&Gamble, Orchid Pharma, Sandoz, Sanofi-Aventis, Sigma-Tau, Tillotts Pharma and Photonamic, as well as its own brand of nutritional supplements. In 2016, Eczacıbaşı Pharmaceuticals Marketing signed an agreement with Zydus Cadila for strategic cooperation in biosimilars that will begin with cancer treatments for which no biosimilars are currently available to Turkey.

Eczacıbaşı Pharmaceuticals Marketing has four business units working with regional representatives around the country. Over 30 district managers and some 300 sales representatives visit more than 25,000 doctors, 2,500 dentists and 5,000 pharmacies on a regular basis. All visits are processed daily and monitored by the sales force automation system.

Eczacıbaşı Pharmaceuticals Marketing entered into a collaboration with new global partners for the development of the biotechnological products, which are considered as one of the most important technologies for the future in Turkey like in the whole world, and already started to put its R&D oriented projects into practice. As the first phase of these projects, which will comprise all competitive facets of the biotechnology, Eczacıbaşı Pharmaceuticals Marketing continues at full steam with the registration of exclusive imported biotechnology products.

Contact Person
Name: Özer Tümer MD
Position: Medical and Regulatory Affairs Director
Phone: +90 212 350 84 38
E-mail: ozer.tumer@eczacibasi.com.tr



Company Name:
Florabio
Company Web:
www.florabio.com.tr

Turkish Biopharmaceuticals Platform

Florabio is the one and only life science Research and Development company (CRDO) in Turkey and MENA with proprietary technology, know-how and experience in developing and manufacturing therapeutic proteins with competitive lead times and in the most cost-effective way. Its technology and expertise is based on cell cultures.

Florabio specializes in Cell Line Development, Media Development and Process Development, both in small and large scales of up to 50 litres. With its proprietary technology and know-how, Florabio is able to reduce the manufacturing cost of biopharmaceuticals for its clients, thereby providing cheaper, more secure and assured of the highest standards in quality. Its clients gain access to its state of the art manufacturing technology and also benefit from Florabio's service to produce biopharmaceuticals cost-effectively and securely. This is Florabio's inspiration and what drives it to better its work and products each and every day.

Florabio's services are:
- Cell Line Development (Cell Culture Based)
- Media Development
- Media Optimization
- Feed Development
- Small Scale Upstream Process Development up to 5 L
- Small Scale Downstream Process Development up to 5 L
- Scale-up Services up to 50 litres
- Consultancy
- Media Supply
- Training – via FlorabioACADEMy

Florabio ACADEMy, Florabio's sister company, was established to provide customized learning and consulting services that add quantifiable value to businesses by improving the performance of both their people and their processes. FloraBio ACADEMY focuses on delivering skills that are immediately useful in day-to-day operations and services that help define and achieve business objectives:

- Learning programs are defined after thorough analysis of the knowledge level of the personnel through management interviews.
- Everything Florabio delivers is designed to ensure the achievement of specific, agreed upon and quantifiable business objectives.
- Strategic thinking about unit operations and sharing of this knowledge upstream and downstream of one's own area is embedded in our offerings.

FloraBio ACADEMY has a core team of seasoned biopharmaceutical professionals, each with 20+ years of dedicated experience gained in world-reknown Biopharma companies, as well as an extensive network of subject matter experts ready to support your needs. It is dedicated to providing its partners with all the knowledge required to design and implement biopharmaceutical processes, as well as ensuring the transfer of high-level management skills needed to run an efficient and effective "Bio-Business".

Contact Person
Name: Cem Erdem
Position: COO – General Manager
Phone: +90 532 374 04 70
E-mail: cerdem@florabio.com.tr

Company Name:
Hasbiotech Pharmaceuticals
Company Web:
www.hasbiotech.com

Turkish Biopharmaceuticals Platform

Founded in 2009, Hasbiotech has taken into consideration the needs of Turkish medicine and focused on innovative and pioneering therapies when establishing its vision and mission. The product portfolio of Hasbiotech consists primarily of reference drugs, including biotechnological products used for hematologic, metabolic and chronic diseases; oncology and wound treatment in particular.

HEBERPROT-P, an authorized product of Hasbiotech, contains EGF, is used to prevent amputations due to diabetic foot ulcer, and is a niche product in its field. In Turkey, thousands of patients have been saved from foot amputation with the Heberprot-P therapy since 2012. Successful treatments in Turkey have appeared in world's leading scientific journals.

In addition to adaptation of biotechnological products, the company gives primacy to strategy of developing reference products, which has been long awaited by our country, in combination with the academic knowledge in Turkey. Within the scope of this mission, joint projects with many countries are being conducted and a future is being prepared that will make Turkey a world player.

Specific therapeutic areas on which Hasbiotech focuses within this framework have been started with the treatment of diabetes-associated chronic wounds, and continued with therapeutic vaccine in lung cancer. In the coming years, mainly products aiming at target-specific treatment in oncology and products that prevent death from myocardial infarction in cardiology as well as unmet needs in medicine will be aimed. The R&D and/or clinical studies for all the advanced biotechnological products Hasbiotech developes or plans are designed to meet the world standards and mainly conducted in its country. Following completion of these stages, production of the products will be made in its site located at Kayseri.

The biotechnological drug manufacturing plant Hasbiotech has started to build in Kayseri has been designed to have high technology and meet world quality standards on a land of 30,000 square meters including an indoor space of 9240 square meters. The rough construction work has been completed, and the plant is aimed to put into operation in 2020 after all required permissions are obtained.

In the field of R&D and Business Development, apart from its standard roles, Hasbiotech has undertaken a mission to take a global and innovative approach which will set an example for Turkey. Within this context, the company is open to cooperation to benefit from co-development, in-licensing, out-licensing and contract manufacturing opportunities by building long-term relationships with its possible business partners especially in Europe, Middle East, North Africa and CIS countries for its current products and ongoing projects.

Contact Person
Name: Neşe Öztürk Coşkun
Position: Business Development Manager
Phone: +90 549 806 56 59
E-mail: nozturk@hasbiotech.com

Company Name:
ILKO Pharmaceuticals
Company Web:
www.ilkogen.com.tr

Turkish Biopharmaceuticals Platform

The current representative of more than 50 years experience in the Turkish pharmaceutical industry, ILKO Pharmaceuticals continues its efforts to increase the standards of living in Turkey and in the world with vanguard and innovative approaches based on its past experiences.

The roots of ILKO Pharmaceuticals are based on the drugstore pharmacology of the late Mr. Mustafa Öncel -one of the second generation pharmacists of Turkey- that started with magistral drug production in the 1960s and his investments in the pharmaceuticals industry.

Based on the principle that the most important two factors for effectiveness in the pharmaceutical industry are R&D and production means, ILKO Pharmaceuticals established 'ILKO Research and Development Center' in 2009 in Hacettepe University Techno City, and the company also opened 'ILKO Pharmaceutical Production Plants' in 2012 in Konya 3rd Organized Industry Zone to start its operations in the pharmaceutical industry. ILKO Pharmaceuticals Production Plants is the biggest pharmaceutical industry investment realized in Anatolia so far.

In 2014, ILKO Pharmaceutical Production Plants received confirmation of conformity to the European GMP (Good Manufacturing Practices) from the MHRA (Medicines and Healthcare Products Regulatory Agency of the UK). With this MHRA approval, ILKO Pharmaceuticals continues to get licenses in and export products to 25 countries located in different regions.

ILKOGEN is the unique innovation in Turkey with the scope of developing and manufacturing novel biotechnological pharmaceuticals as well as next generation biobetter and biosimilar products.

Founded in 2013 as a joint venture by the Turkish pharmaceutical company ILKO, Inc. and the South Korean biotechnology company, Genexine Inc. ILKOGEN is the pioneer international research and marketing investment on bio-drug.

This international partnership is established to cover the clinical trials of the best-in-class, long acting, 3rd generation, G-CSF developed by hyFc technology propriety to Genexine. The technology and know-how transfer also enables ILKOGEN to develop novel projects, depending on the strong technological and industrial basis arising from more than 50 years of deep experience of ILKO and strong R&D expertise of Genexine. In this respect, the first ILKOGEN branded products are going to be introduced to the international markets in the following three years.

Contact Person
Name: Ali Taha
Position: Business Development Manager
Phone: +90 212 280 70 55
E-mail: ataha@ilkogen.com.tr

Company Name:
Koçak Farma

Company Web:
www.kocakfarma.com

Koçak Farma was founded in 1971. The company manufactures conventional medicine, biotechnological/biological medicine, intravenous (I.V.) solutions and active pharmaceutical ingredients (API). Koçak Farma Production facilities in Çerkezköy Organized Industrial Region is established on 140.000 m² area and has 100.000 m² indoor area with 500 million unit/year production capacity. The I.V. Solution Production facilities in İstanbul/Ayazağa is established on 50.000 m² area and has 150 million unit/year production capacity.

Koçak Farma Group has around 2000 employees. The company is listed in İSO (İstanbul Chamber of Industry) 2016 Turkey's Top 500 Industrial Enterprises Survey. Koçak Farma has an "R&D Center" approved by Ministery of Science, Industry and Commerce. 100 specialists and scientists are doing research in the center.

Koçak Farma facilities consist of 7 dedicated premised which are approved by EU authorities and have EU GMP certificate: Conventional Medicine Production Facilities, Oncology Medicine Production Facilities, Hormone Medicine Production Facilities, Carbapenem Medicine Production Facilities, Penicilline Medicine Production Facilities, Biotechnological/Biological Products Production Facilities, API Production Facilities.

Koçak Farma has the capability of manufacturing all pharmaceutical forms in these dedicated areas. Koçak Farma has manufactured the below products for the first time in Turkey: Biosimilar products, oncology products, soft gelatine products, sterile cartridges, lyophilized ampoules and vials, prefilled syringes, ready to use insulin pens.

Koçak Farma has launched the first Biosimilar product in EU and Turkey, "Enoxaparin Sodium" in prefilled syringe form in 2012 in Turkey. Koçak Farma has launched the first locally manufactured Insulin with Insulin Glargine API, "Glarin 1oo U/ml Solution for Injection in Pen for SC Use" in 2017.

Koçak Farma will manufacture Insulin Analogues, Monoclonal Antibodies (mAbs), bacterial, viral and recombinant vaccines in its Biotechnological/Biological facilities in Çerkezköy Organized Region which is the first facility in this area in Turkey.

Koçak Farma is a leading company in the world in Oncology area with its broad product portfolio. It is manufacturing one of every 2 units of Oncology products used in Turkey.

Koçak Farma is exporting its products to more than 50 countires in 5 continents, especially to EU countries including Germany, France, Italy, Spain etc. , from its facilities with EU GMP approval.

Contact Person
Name: Cem Koçak
Position: External Affairs and Business Development Director
Phone: +90 212 410 39 50
E-mail: ckocak@kocakfarma.com

Company Name:
Liba Laboratories
Company Web:
www.liba.com.tr

Liba Laboratories was founded in 1945 by Lale and Necip Barlas in Istanbul. As one of the first pharmaceuticals companies of the Republic of Turkey, Liba's top priority has been contributing to public health and well-being. Liba has also prioritized and supported the development and progress of the Turkish pharmaceuticals industry for 73 years, and will continue to do so.

Its business consists of locally produced Liba-branded products and imported products that it distribute. Its net sales in 2017 were 14.3 m units and 30 m Euro. Liba is proud of its yearly growth rates, %31 in units, well above the market's growth rate. Its strategy is to support this growth through new products in development as well as new international cooperations.

Liba's main focus is ophthalmology and it is also active in the fields of psychiatry, neurology, dermatology and analgesics.

Liba's vision is to continue its work through the selection of innovative products in highly specific areas for the presentation to the Turkish healthcare sector under purely ethical standards.

Contact Person
Name: Lale Barlas
Position: Business Development Director
Phone: +90 532 686 19 91
E-mail: lale.barlas@liba.com.tr

Company Name:
Mustafa Nevzat Pharmaceuticals
Company Web:
www.mn.com.tr

Turkish Biopharmaceuticals Platform

Mustafa Nevzat (MN) Pharmaceuticals, originally established under the name, `Mustafa Nevzat Laboratuvarı` in Üsküdar, İhsaniye in 1923, is one of the long-established pharmaceutical companies in Turkey. MN Pharmaceuticals is a leading company to break many grounds in Turkish pharmaceutical industry and contributed to the development of national pharmaceutical industry. Today, our Company, with an experience of 94 years in the pharmaceutical industry, is among the leading drug product (DP) and drug substance (API) manufacturers in Turkey with its expert staff consisting of approximately 1000 employees and all production facilities including API production approved by international authorities such as EU/MHRA and Saudi FDA. The organizational structure of MN Pharmaceuticals consists of general management and headquarters, API and finished product (DP) production facilities and area organization.

The following active substances are manufactured at our four separate manufacturing units in the Raw Materials Production Plants: penicillin group active substances, macrolide group active substances as well as etodolac, granisetron, zoledronic acid, rocuronium bromide, aripiprazole, monosodium ibandronate monohydrate, gemcitabine HCL, dexketoprophen trometamol and imatinib mesylate active substances. Antibiotics, corticosteroids, cardiovascular agents, anti-inflammatory agents, gastrointestinal agents, anti-diabetic agents, central nervous system preparations, and agents for other treatment groups are manufactured at one of the independent plants in where finished pharmaceutical preparations are produced. Injectable Oncolytics Plant, as the second finished products plant, was put into service in 2009. This plant manufactures liquid and lyophilized vials.

Pharmaceuticals manufactured through continuous training, vast knowledge and state-of-the-art technology, and in conformity with the world-class "Current Good Manufacturing Practices (Cgmp)" and "Current Good Laboratory Practices (Cglp)", are intended for human health not only in Turkey but also in many other countries.

Treatment groups involved in the pharmaceuticals portfolio of Mustafa Nevzat İlaç Sanayii A.Ş. include Systemic Anti-Infective Agents, Cardiovascular System, Musculoskeletal System, Digestive System and Metabolism, Corticosteroids, Oncology, Hematology, Central Nervous System, Dermatology (Other), and Immunomodulators.

As at June 12, 2012, Mustafa Nevzat Pharmaceuticals was acquired by Amgen Pharmaceuticals. This acquisition has no effect on the pharmacovigilance activities of our company. The current pharmacovigilance activities are still under way.

Contact Person
Name: Ayla Kurtuluş
Position: General Manager, Technical Operations and External Trade
Phone: +90 212 454 76 00
E-mail: aylak@amgen.com

Company Name:
Nobel Pharmaceuticals
Company Web:
www.nobel.com.tr

Turkish Biopharmaceuticals Platform

Nobel Pharmaceuticals is a leading Turkish pharmaceutical company, headquartered in Istanbul, engaged in the research and development, manufacture, marketing and distribution of pharmaceutical products. With its twenty organizations outside of Turkey and EU-GMP certified manufacturing facilities, Nobel, is a strong and well-respected player in the domestic and international markets, and a gateway to Southeastern Europe and CIS countries.

Nobel as a branded generic company with a strong emphasis on innovation, foresaw the future and focused on new molecule development as an area of strategic importance 15 years ago and launched R&D investments in this area. In 2002, Nobel established an R&D center, which today enjoys a highly qualified team of professionals. This center is dedicated to:

- Discovery and development of new molecules
- Development of generic molecules
- Pharmaceutical formulations and processes
- Analytical research
- Clinical research

Nobel manages activities for all stages of pharmaceutical product development value chain via vertical integration:

When it comes to biotechnology, Nobel has also taken the leadership in its territories. In 2009, Nobel successfully completed the registration of Epobel, the first bio-similar eritropoetin in Turkey. Since its registration, the Epobel's market share has reached 25% among all the Short Acting Erythropoietin products in Turkey.

In 2014, Nobel was the first company who was deemed worthy of the largest Governmental Grant for the First National Biopharmaceutical (Biosimilar mAbs) Development & Production Project.

In 2017, it was also honored as the first domestic company to receive government support in the development of original biotechnological drugs. Now, Nobel has been developing itsvectors & recombinant cell lines and establishing a biotechnology facility in Turkey which will be active in 2018. When it is completed, with is main capacity of 3x1000L (+2x1000L) biotechnological drug manufacturing Nobel, will manufacture Nobel's products, while also perform CDMO activities in the facility.

All biotech investments on biosimilars (mAbs, glycoproteins, enzymes) and original (bio) molecule development are the driving forces of Nobel, and with leading such projects Nobel plans to become the flagship of the biotechnological industry in Turkey.

Contact Person
Name: Hasan Zeytin
Position: Biotechnological Project and New Product Assessment Director
Phone: +90 216 633 62 72
E-mail: hasan.zeytin@nobel.com.tr

Company Name:
Onko Koçsel Pharmaceuticals
Company Web:
www.onkokocsel.com

Onko Koçsel Pharmaceuticals has been serving as a 100% domestic pharmaceutical company in Turkish Health Sector for 30 years. It has products in the fields of oncology, hematology, radiology, rheumatology, immunology, dermatology, neurology, physiotherapy and urology. In 2014, Onko Koçsel Pharmaceuticals established pharmaceutical manufacturing plant with the world's most advanced technology by doing one of the largest industrial investments of recent years in Turkey. Thus, the company both produces oncology medicines, of which 95% are imported to the country in the market, and produce products for other life-saving treatment groups in the non-cytotoxic production area. In addition, Onko Koçsel which is one of the 14 companies in the world with its insulator technology, has GMP approved R&D center which has the same technology as production facility. The company conducts export activities intensively in order to offer its products developed in European and American standards in its R&D center. In addition to production of its own products at its production facility, Onko Koçsel Pharmaceuticals, which has succeeded in getting European GMP certificate for all production lines, provides contract manufacturing services for local and international firms for both domestic and international markets.

Aiming to increase the number of existing licensed products doubled in 5 years, Onko Koçsel Pharmaceuticals is taking firm steps forward to become a global player by representing our country abroad with a dynamic team that closely follows international standards. Knowing that human resources is the key of success, the firm makes the education investments necessary for the development and training of the staff to gain their knowledge about the production of biotechnological products.

Onko Koçsel Pharmaceuticals has been one of the leading companies in the biological product market since its establishment. Onko Koçsel has been one of Turkey's emerging pharmaceutical company with biological products especially in hematology and oncology fields, there are special reserve areas in the plant dedicated to the production of biotechnological products. With the technology transfer agreements made with international pharmaceutical companies, Onko Koçsel adds new products to its portfolio also in the field of biotechnology. The existing facility is capable of filling process of biotechnological products. In order to achieve all phases from the cell culture to the production of finished products, the firm currently carries on work, when the reserve fields of the facility are brought into use through investment.

Contact Person
Name: Tuğçe Koç
Position: General Manager
Phone: +90 216 544 90 00
E-mail: tkoc@onkokocsel.com

Company Name:
Pharmactive Pharmaceuticals
Company Web:
www.pharmactive.com.tr

Pharmactive Pharmaceuticals founded in December 2010 with the conception of "how happy is one who remediate a sickness" with more than 200 million dollars investment and has one of the biggest and highest quality production facilities in Europe.

GMP certified Pharmactive production facility on the area of 108.000 sqm has capacity of producing 330 million units on liquid, semi solid and solid lines. In February 2015, Pharmactive gained the right of having European GMP certificate which is globally prestigious and given by the BfArM, one of the respected authorities.

In 2017 this certificate was renewed. Pharmactive's R&D center within its modern facilities on 3.200 sqm has been approved by Turkish Ministry of Science, Industry and Technology in the rank of 9. Growing both in Turkish and international markets with wide product range, Pharmactive is the production partner of global pharmaceutical firms such as Abbott, Astra Zeneca, GlaxoSmithKline, Reckitt Benckiser, Chiesi and Sandoz thanks to its flexible production ability and high production capacity.

In 2016, Pharmactive partnered with Korean Biotechnology firm Polus and has exclusive rights for 34 countries for biotechnological products. First production facilities will be in Korea and the second facilities are going to be built in Turkey in 2019.

Pharmactive with the goal of becoming one of the 5 biggest pharmaceutical companies, by producing high quality medicine with suitable costs will keep being the hope of patients in Turkey and the world.

Contact Person
Name: Yunus Sancak
Position: Business Development Manager
Phone: +90 212 604 55 00 - 3071
E-mail: yunus.sancak@pharmactive.com.tr

Company Name:
Teva Pharmaceuticals
Company Web:
www.teva.com.tr

Teva is one of the 10 largest pharmaceutical companies in the world. It aims to create value for both patients and authorities that regulate the healthcare system and to increase access to quality healthcare solutions. With the acquisition of Actavis Generics worldwide, Teva's international reach, Research-Development (R&D) capacity and product portfolio have significantly increased. With 1,800 drugs and 16,000 products, Teva is healing 250 million people every day around the world.

Teva's position in the global pharmaceutical market is based on a robust and balanced business model that is quite different from other companies:

1. Teva specializes in both the original and the equivalent drug market.
2. In the field of OTC, Teva exclusively collaborates with world leader Procter & Gamble.
3. Teva is active at both equivalent, original drug and OTC R&D. This is defined as integrated R&D.
4. Teva is the world's leading producer of raw materials for all pharmaceutical manufacturers.

Turkey is one of the five focal Growth Markets, Teva's largest geographical region, and has a strategic importance. In 2007, Teva acquired Med Pharmaceuticals, a Turkish company, and began its operations in Turkey. In 2016, Teva changed its trademark to "Teva Turkey". Since then, it has been offering equivalent and innovative products produced in world standards for the use of Turkish medicine.

Teva Turkey, focuses on disease areas such as Central Nervous System (CNS) and Multiple Sclerosis (MS) specifically, Oncology, Respiratory and OTC & Dermatology where its Teva brand is uniquely positioned and globally recognized. It is working toward a single, common goal every day, through its original and equivalent treatments in all of these treatment areas: to improve health and make people feel better.

Contact Person
Name: Melek Çıkar
Position: Admin & Corporate Communications Manager
Phone: +90 216 656 67 00
E-mail: melek.cikar@teva.com.tr

TRPHARM aims to construct one of the pioneer biotechnology manufacturing facilities with its facility in Çerkezköy/Tekirdağ where the groundbreaking cerenomy was done in 2016. The facility was designed to be able to manufacture in high capacity to meet the demands of Turkey as well as Eurasian, Middle East and Africa countries.

The facility in where several innovative products especially monoclonal antibodies will be able to manufactured, is designed to have 9 molecule or 200 kg manufacturing capacity. Beside the biotechnological products, TRPHARM also carries on business in Oncology&Hematology, Inflammation and Rare Diseases areas.

On 30 th of January 2018, TRPHARM got the marketing authorization for the first biosimilar of Rituximab in Turkey and the world for indications of NHL and CLL.

Contact Person

Name: Funda Kaya

Position: Quality Assurance Manager

Phone: +90 212 386 31 78

E-mail: funda.kaya@trpharm.com

Company Name:

TRPHARM Pharmaceuticals

Company Web:

www.trpharm.com

Turkish Biopharmaceuticals Platform

Company Name:
Turgut Pharmaceuticals
Company Web:
www.turgutilac.com.tr

Turkish Biopharmaceuticals Platform

The main objective of Turgut Pharmaceuticals is to develop, manufacture and market high-quality biotechnological products for Turkish and global markets with the international standards-compliant biotechnology infrastructure that has been created based on R&D in Turkey.

Establishing the Biotechnology Group in early 2014 as part of a strategic decision, Turgut Pharmaceuticals redefined its priorities and main objectives, and concentrated its operations and investments in the field of biotechnology. In this framework, the company determined basic requirements for developing and manufacturing world-class biosimilar drugs by initially collaborating with domestic and international expert organizations, identified shortcomings by examining the biotechnology infrastructure in our country, and came up with a strategic plan based on tangible data that incorporates solutions to establish a sustainable biotechnology infrastructure as quickly as possible taking into account the conditions prevalent in our country and to develop and launch high-quality biosimilar monoclonal antibodies, and put the plan into effect. The strategic plan covers three main fields of activity, as well as the establishment of a world-class biotechnology platform in Turkey:

1. R&D-Based Product Development
In 2015, Turgut Pharmaceuticals Biotechnology Development Center, whose management and ownership belong entirely to Turgut Pharmaceuiticals, was established and operationalized in the Acibadem Mehmet Ali Aydinlar University Campus. A biotechnology platform was established at this Center in order to develop world-standard biotechnology products based on R&D. Now, Turgut Pharmaceuticals Biotechnology Center has become Turkey's first biotechnology R&D Center established in the field of recombinant monoclonal antibody technology equipped with the state-of-the-art technological infrastructure and qualified human resource capable of performing prototype antibody manufacturing, as well as all comparative protein analyses with the reference product as required by EMA and FDA rules.

2. GMP Biotechnology Manufacturing Facility
A GMP biotechnology manufacturing facility was designed in collaboration with experts from Merck in compliance with the criteria established by EMA, Turkish Ministry of Health and other international authorities in Gebze Organized Industry Site (GOSB), and the foundation of this plant was laid in June 2016. Construction of the building was completed. With the installation of technical equipment and production lines, it has been planned to become operational in early 2018.

3. Domestic and International Collaborations
Turgut Pharmaceuticals established collaborations with domestic and international expert organizations in the fields of training, technology and consultancy in order to develop and manufacture high-quality biotechnology products.

Contact Person
Name: R. Serdar Alpan, MD, PhD, MSc
Position: Head of Biotechnology Group
Phone: +90 212 280 12 51
E-mail: salpan@turgutilac.com.tr

VEM Pharmaceuticals, which has been active in healthcare industry since 2000, offers many medicinal products in the areas of Nephrology, Pulmonary Diseases, Gastroenterology, Pediatry, Urology, Dermatology, Cardiology and Cardiovasular Surgery, Intensive Care, Anesthesia to service of Turkish Medicine.

VEM Pharmaceuticals is a national company, which is conscious that Turkey must be strong in drug industry and with this awareness it started investmening to set up its own manufacturing facility in 2011. Vem Pharmaceuticals owns a factory in Cerkezkoy Industrial Zone with a 22.500 m2 closed area and continues to work both for domestic market and for export robustly.

As of the end of 2018, VEM Pharmaceuticals' biotechnological production facility will become operational and product development from mammalian cell lines (CHO) will begin. Herein product developments in areas such as cancer, nephrology etc. are planned. The pipeline of biosimilar products will be expanded in the near future with the collaboration of multinational biotech companies.

Contact Person
Name: Ayşe Göklü Şenol
Position: Business Development and Regulatory Affairs Officer
Phone: +90 505 321 25 62
E-mail: ayse.goklu@vemilac.com

Company Name:
Vem Pharmaceuticals
Company Web:
www.vemilac.com

Turkish Biopharmaceuticals Platform

Turkish
Biopharmaceuticals
Platform

Nef 09 B Blok Kat: 10 Sanayi Mah. Hümeyra Sok. No: 7 34415 Kağıthane / İstanbul Tel: +90 (212) 353 11 20